Meta-analysis of the Efficacy and Safety of Ⅹa Factor Inhibitors in the Prevention and Treatment of Venous Thromboembolism in Cancer Patients
- VernacularTitle:Ⅹa因子抑制剂预防和治疗癌症患者静脉血栓栓塞有效性和安全性的Meta分析
- Author:
Jiajun ZHANG
1
;
Yanming YANG
1
;
Yaqing YANG
1
;
Shanshan LI
1
;
Zhiying WENG
1
Author Information
1. School of Pharmaceutical Science & Yunnan Key Labora tory of Pharmacology for Natural Products，Kunming Medical University，Kunming 650500，China
- Publication Type:Journal Article
- Keywords:
Ⅹa inhibitors;
Cancer;
Venous thromboe mbolism;
Meta-analysis;
Efficacy;
Safety
- From:
China Pharmacy
2020;31(6):729-733
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE：To systematicall y evaluate the efficacy and safety of a new oral anticoagulant Ⅹ a inhibitor （apixaban，rivaroxaban，edoxaban）in the prevention and treatment of venous thromboembolism （VTE）in cancer patients ，and to provide evidence-based reference for rational use of drugs in clinic. METHODS ：Retrieved from Cochrane Library ，PubMed， Embase，CBM，CNKI，VIP and Wanfang database ，randomized controlled trials （RCTs）about Ⅹa inhibitor （trial group ）versus routine treatment or placebo （control group ）in the prevention and treatment of VTE in cancer patients were collected. After literature screening ，data extraction and quality evaluation was evaluated by using biasrisk evaluation tool recommended by Cochrane System Evaluator M anual 5.1.0，and Meta-analysis was conducted by using Rev Man 5.3 software. RESULTS ：A total of 7 RCTs were included ，including 5 666 patients. Meta-analysis showed that recurrent rate of VTE in trial group was significantly lower than control group [RR ＝0.58，95％CI（0.47，0.71），P＜0.000 01]；there was no statistical significance in the incidence of major bleeding [RR ＝1.12，95％CI（0.67，1.85），P＝0.67] and clinically relevant non-major bleeding [RR ＝1.06，95％CI（0.72，1.55）， P＝0.77] between 2 groups. CONCLUSIONS ：Ⅹa inhibitors can effectively reduce the recurrent risk of VTE in cancer patients ， safety comparable with routine treatment （placebo）.
